US5032109A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Electrolytic transdermal delivery of polypeptides
Assignee: Drug Delivery Systems Inc
•
Filing: 1989-11-01
•
Granted: 1991-07-16
•
Expires: 2009-11-01
Abstract
Abstract The invention comprises in combination: (a) a polypeptide having from about three to about 20 peptide units in aqueous solution or suspension, and (b) an electrolytic device for transdermal transport of the polypeptide to the bloodstream of the patient. It may be useful to enhance the transdermal delivery of the polypeptide by adding an aqueous cosolute/cosolvent with negative Setschenow constants. The electrolytic device preferably comprises a hydrophilic reservoir containing a supply of the aqueous polypeptide solution or suspension, an electric battery, two extended contacts, and optionally a semipermeable membrane between the reservoir and the patient's skin. Representative polypeptides include oxytocin, angiotensin I, II, and III, substance P, vasopressin, lypressin, desmopressin, leuprolide acetate, antripeptin, and the like.
Inventors
- 👤 Dan Sibalis
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 13:23
CPC Classifications
A; A61; A61N; A61N1/00; A61N1/02; A61N1/04; A61N1/0404; A61N1/0408; A61N1/0428; A61K; A61K9/00; A61K9/0002; A61K9/0009; A61N1/0448
Claims Analysis
Total Claims: 28
Claim 1
Independent Claim
77 words
An electrolytic transdermal patch including an electrical circuit with an electrical power source for delivering at least one drug to the bloodstream of the patient comprising in combination: (a) at least one polypeptide having from about three to about 20 peptide units, and (b) means for transdermal transport of the polypeptide characterized by a current density from about 0.5 microampere/cm 2 to about 1 milliampere/cm 2 whereby the skin of the patient is neither irritated nor erythematized.
Claim 2
Dependent Claim
77 words
An electrolytic transdermal patch including an electrical circuit with an electrical power source for delivering at least one drug to the bloodstream of the patient comprising in combination: (a) at least one polypeptide having from about three to about 20 peptide units, and (b) means for transdermal transport of the polypeptide characterized by a current density from about 0.5 microampere/cm 2 to about 1 milliampere/cm 2 whereby the skin of the patient is neither irritated nor erythematized.
Claim 3
Dependent Claim
27 words
A transdermal patch as in claim 1, wherein the means for transport comprises a battery, an anode, a cathode, a drug reservoir, and barrier means between electrodes.
Claim 4
Dependent Claim
20 words
A transdermal patch as in claim 2, further comprising a semipermeable membrane on the skin side of the drug reservoir.
Claim 5
Dependent Claim
26 words
A transdemal patch as in claim 1, wherein the current density of the patch is from about 0.5 ua/cm 2 to about 10 ua/cm 2 .
Claim 6
Dependent Claim
27 words
A transdermal patch as in claim 1, further comprising at least one compound selected from the group consisting of buffering agents, chelating agents, antioxidants, preservatives, and biocides.
Claim 7
Dependent Claim
15 words
A transdermal patch as in claim 1, further comprising an aqueous solvent for the polypeptide.
Claim 8
Dependent Claim
12 words
A transdermal patch as in claim 6, further comprising a dissociating cosolvent.
Claim 9
Dependent Claim
47 words
A transdermal patch as in claim 7, wherein the dissociating cosolvent is selected from the group consisting of urea, guanidine salt, butanol, 2-butanol, water-soluble amides with more than three carbon atoms, sodium and potassium iodide, sodium perchlorate, sodium butyrate, and any other salt with negative Setschenow constants.
Claim 10
Dependent Claim
123 words
A transdermal electrolytic patch for delivering at least one drug directly to the bloodstream of the patient as in claim 1, comprising: (a) an active ingredient comprising at least one polypeptide having from three to twenty peptide units having pharmacological activity in an application selected from the group consisting of alleviating diabetes insipidus, gastrointestinal hemmorhage, induction of childbearing labor, antidiuretic, alleviating prostate cancer, inhibition of LH-RH FSH, analgesic, hormonal regulation, insulin regulation, growth hormone inhibition, modulation of blood pressure, regulation of body fluids, and combinations thereof; and (b) electrolytic means for transdermal transport of the polypeptide characterized by a current density from about 0.5 microamp/cm 2 to about 1 milliamp/cm 2 , whereby the skin of the patient is neither irritated nor erythematized.
Claim 11
Dependent Claim
52 words
A transdermal patch as in claim 9, wherein the polypeptide is selected from the group consisting of vasopressin, desmopression, oxytocin, bypressin, leuprolide acetate, dynorphin A. dynorphin B, met-enkaphalin, leuenkephalin, thyrotropin, releasing hormone, alphal-melancyte stimulating hormone, beta-melancyte stimulating hormone, neurotensin, substance P, somatostatin, angioxensin I, angiotensin II, angiotensin III, atriopeptin, and combinations thereof.
Claim 12
Dependent Claim
28 words
A transdermal patch as in claim 9, wherein the electrolytic means comprises a battery, an anode, a cathode, a drug reservoir, and a barrier means between the electrodes.
Claim 13
Dependent Claim
15 words
A transdermal patch as in claim 9 further comprising an aqueous solvent for the polypeptide.
Claim 14
Dependent Claim
33 words
A transdermal patch as in claim 9, further comprising at least one compound from the group consisting of buffering agents, chelating agents, antioxidants, preservatives, biocides, and dissociating cosolvents with a negative Setschenow constant.
Claim 15
Dependent Claim
29 words
A transdermal patch as in claim 9, further comprising current controlling means whereby the current density of the patch is from about 0.5 to about 10 microamps./cm 2 .
Claim 16
Dependent Claim
50 words
A transdermal patch as in claim 13, wherein the dissociating cosolvent is selected from the group consisting of urea, alkylderivatives of urea, guanidine salt, butanol, 2-butanol, water-soluble amides with more than three carnon atoms, sodium iodide, potassium iodide, sodium perchlorate, sodium butyrate, and any other salt with negative Setschenow constants.
Claim 17
Dependent Claim
20 words
A transdermal patch as in claim 11, further comprising a semipermeable membrane on the skin side of the drug reservoir.
Claim 18
Dependent Claim
100 words
A transdermal patch for delivering at least one drug directly to the bloodstream of the patient comprising in combination: (a) a circuit including an electrical power source for supplying power to and electrically connected to at least one electrical contact at a drug reservoir and means for controlling the current density of the patch from about 0.5 microampere/cm 2 to about 10 microampere/cm 2 ; and (b) an active ingredient comprising at least one polypeptide having from about three to about 20 peptide units in an aqueous drug reservoir; whereby the skin of the patient is neither irritated nor erythematized.
Claim 19
Dependent Claim
100 words
A transdermal patch for delivering at least one drug directly to the bloodstream of the patient comprising in combination: (a) a circuit including an electrical power source for supplying power to and electrically connected to at least one electrical contact at a drug reservoir and means for controlling the current density of the patch from about 0.5 microampere/cm 2 to about 10 microampere/cm 2 ; and (b) an active ingredient comprising at least one polypeptide having from about three to about 20 peptide units in an aqueous drug reservoir; whereby the skin of the patient is neither irritated nor erythematized.
Claim 20
Dependent Claim
21 words
A transdermal drug patch as in claim 17, further comprising a semipermeable membrane on the patient side of the drug reservoir.
Claim 21
Dependent Claim
28 words
A transdermal drug patch as in claim 17, further comprising at least one compound selected from the group consisting of buffering agents, chelating agents, antioxidants, preservatives, and biocides.
Claim 22
Dependent Claim
19 words
A transdermal drug patch as in claim 17, wherein at least one polypeptide is LH-RH analog further comprising testosterone.
Claim 23
Dependent Claim
19 words
A transdermal drug patch as in claim 17, wherein at least one polypeptide is LH-RH analog further comprising Flutamide.
Claim 24
Dependent Claim
20 words
A transdermal drug patch as in claim 17, further comprising covering means over at least part of the drug reservoir.
Claim 25
Dependent Claim
21 words
A transdermal patch as in claim 17, further comprising a water-destructuring agent in the active ingredient in the aqueous drug reservoir.
Claim 26
Dependent Claim
52 words
A transdermal patch as in claim 23, wherein the water-destructuring agent is selected from the group consisting of urea, alkylderivatives of urea, guanidine salt, butanol, 2-butanol, water-soluble amides with more than three carbon atoms, sodium iodide, potassium iodide, sodium perchlorate, sodium butyrate, any other compound with negative Setschenow constants, and mixtures thereof.
Claim 27
Dependent Claim
14 words
A transdermal drug patch as in claim 24, wherein the water-destructuring agent is urea.
Claim 28
Dependent Claim
15 words
A transdermal drug patch as in claim 24, wherein the water-destructuring agent is potassium iodide.
References Cited (Backward Citations)
US4767401A
Cited
SU591194A1
Cited
SU620265A1
Cited
SU1076124A1
Cited
SU978835A1
Cited
US4416274A
Cited
SU1017348A1
Cited
US4459226A
Cited
US4710497A
Cited
US4704282A
Cited
US4725439A
Cited
US4624665A
Cited
US4702732A
Cited
US4713244A
Cited
US4786278A
Cited
US4752285A
Cited
US4752285B1
Cited
EP0252732A2
Cited
US4731049A
Cited
US4878892A
Cited
US4940456A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-07-15 | 1995-01-14 | 1995-07-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-07-15 | 1999-01-14 | 1999-07-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-07-15 | 2003-01-14 | 2003-07-16 | $7700.00 | Window Closed / Lapsed |